Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies.
|Partner||Johnson and Johnson|
|Investment Portfolio||Fund Investment|
|Co-Investors||The University Of Nottingham Parkwalk, Angel Cofund, Wren Capital University of Bristol Enterprise Fund|
May 13 2017
o2h group update: Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)